References
1. Varadhachary, G. R. (2007). Carcinoma of Unknown Primary Origin. Gastrointestinal Cancer Research : GCR, 1(6), 229–235.
2. Kwee TC, Basu S, Cheng G, Alavi A. FDG PET/CT in carcinoma of unknown primary. European Journal of Nuclear Medicine and Molecular Imaging. 2010;37(3):635-644. doi:10.1007/s00259-009-1295-6.
3. George Pentheroudakis, Evangelos Briasoulis, Nicholas Pavlidis. Cancer of Unknown Primary Site: Missing Primary or Missing Biology?. The Oncologist 2007; 12:418425; doi:10.1634/theoncologist.12-4-418
4. The Bethesda handbook of clinical oncology third edition, page 388
5. Chevalier TL, Cvitkovic E, Caille P, Harvey J, Contesso G, Spielmann M, Rouesse J. Early Metastatic Cancer of Unknown Primary Origin at PresentationA Clinical Study of 302 Consecutive Autopsied Patients. Arch Intern Med. 1988;148(9):2035-2039
6. Regelink, G., Brouwer, J., de Bree, R. et al. Eur J Nucl Med (2002) 29: 1024
7. Wahl RL, Buchanan JW, eds. Principles and practice of positron emission tomogramphy. Philadelphia, Pa: Lippincott Williams & Wilkins, 2002
8. Alberini JL, Belhocine T, Hustinx R, et al. Whole body PET using FDG in patients with metastasis of unknown primary tumours (CUPS). Nucl Med Commun 2003;24:10 81-1086.
9. Bohuslavizki KH, Klutmann S, Kroger S, et al. FDG- PET detection of unknown primary tumours. J Nucl Med 2000;41: 816-822.
10. Kole AC, Neuweg OE, Pruim J, et al. Detection of unknown occult primary tumours using PET. Cancer 1998;82: 1160-1166.
11. Pelosi E, Pennone M, Deandreis D, Douroukas A, Mancini M, Bisi G. Role of whole body positron emission tomography/ computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor meta-stases from unknown primary site. Q J Nucl Med Mol Imaging 2006;50:15–22
12. Hawkins RA, Hoh CK, Dahlbom M, et al. PET cancer evaluation with 2-(18 F)-2-deoxy-D-glucose, J Nuc Med 1994; 32:1555-1558.
13. Wartski M, Stanc EL,Gontier E,et al. In search of an unknown tumour presenting with cervical metastases: Performance of hybrid FDG-PET-CT. Nucl Med Commun 2007;28:365-371
14. Bohuslavizki KH, Klutmann S, Kroger S, et al. FDG- PET detection of unkn-own primary tumours. J Nucl Med 2000;41: 816-822.
15. Nanni C, Rubello D, Castellucci P, et al. Role of FDG-PET-CT imaging for the detection of an unknown primary tum-ours preliminary results in 21 patients. Eur J Nucl Med Mol Imaging 2005;32 :589-592.
16. Hawkins RA, Hoh CK, Dahlbom M, et al. PET cancer evaluation with 2-(18 F)-2-deoxy-D-glucose, J Nuc Med 1994; 32:1555-1558.
17. Paul SAM, Stoeckli SJ, von Schulthess GK, et al. FDG- PET and PET/CT for the detection of the primary tumor in patients with cervical non- squamous cell carcinoma metastasis of an unknown primary.
18. Lassen U, Daugaard G, Eigtved A, et al. 18-F FDG Whole body PET in patients with unknown primary tumours (UPT). Eur J Cancer 1999;35(7):1076-1082.
19. Abruzzese JL, Lenzi R, Raber MN, et al. The biology of unknown primary tumours. Semin Oncol 1993;20: 238-243.
20. Frost P, Levin B. Clinical implications of metastatic process. Lancet 1992;339: 1458-1461.
21. Frost P. Unknown primary tumors: an example of accelerated (type 2) tumor progression. Basic Life Sci 1991;57: 233-237.
22. Knobber D, Lobeck H, Steinkamp HJ, Does malignant lateral cyst still exists? HNO 1995; 43:104-107.
23. Schoder H, Heung HWD, Gonen M, et al. Head and neck cancer: clinical usef-ulness and accuracy of PET/CT image fusion. Radiology 2004; 231:65-72.
24. Strauss LG. Fluorine -18 deoxyglucose and false positive results: a major problem in the diagnostics of oncolo-gical patients. Eur J Nucl Med 1996;23: 1409-15.
DOI: https://dx.doi.org/10.18535/jmscr/v5i2.65
